Over the past few decades, colorectal cancer (CRC) treatment has changed dramatically. What used to be a “one-size-fits-all” approach is now a highly personalized process, with treatments chosen based on the unique biology of each patient’s tumor.
Today, before starting treatment, doctors often test CRC tumors for certain genetic and molecular markers. These tests can reveal:
- BRAF mutations – such as the BRAF V600E mutation, found in about 10% of people with metastatic CRC, often linked to more aggressive disease.
- KRAS and NRAS mutations – which help determine whether certain targeted therapies will work.
- Microsatellite instability (MSI) or mismatch repair (MMR) status – which can identify patients who may benefit from immunotherapy.
- HER2 amplification – a less common change that can be treated with drugs designed for HER2-positive cancers.
- NTRK fusions – rare changes that open the door to highly targeted therapies.
The goal of this testing is simple: the more we know about a tumor’s genetic “fingerprint,” the more precisely we can match it with the right treatment. This is the core of personalized medicine, and it’s transforming outcomes for patients.
The BREAKWATER Trial – Using Melanoma Drugs in Colorectal Cancer
One of the most exciting examples of this progress is the BREAKWATER trial. This large Phase III clinical study focused on patients with BRAF V600E-mutant metastatic colorectal cancer—a type of cancer that has historically been difficult to treat and has a poorer prognosis.
The trial compared three treatment approaches:
- Standard chemotherapy (mFOLFOX) with or without an anti-VEGF drug.
- Encorafenib plus cetuximab (EC) – a targeted therapy combination with one drug already used in melanoma, now adapted for CRC.
- mFOLFOX plus EC – combining chemotherapy with targeted therapy.
Encorafenib blocks the BRAF mutation’s cancer-driving signal, while cetuximab targets EGFR, stopping cancer cells from bypassing the BRAF blockade and finding “escape routes” through EGFR to keep growing.
What the Results Showed
Cancer trials often measure success in two key ways:
- Progression-Free Survival (PFS): how long a patient lives without their cancer getting worse.
- Overall Survival (OS): how long a patient lives after starting treatment, regardless of whether the cancer grows.
In BREAKWATER, adding EC to chemotherapy nearly doubled PFS—from about 7 months to around 13 months. Even more impressively, OS doubled—from about 15 months to about 30 months.
These improvements are remarkable for a cancer type that has traditionally been resistant to major survival gains.
Side Effects and Quality of Life
The most effective treatment was EC plus chemotherapy, but not everyone can tolerate the side effects of aggressive chemotherapy.
The study found that EC alone provided similar PFS to chemotherapy but with fewer severe side effects (42% with EC alone vs. 67% with chemotherapy). This is important because serious side effects not only reduce quality of life but can also limit a patient’s ability to receive future treatments.
Why This Matters for Patients
For patients who are fit enough, EC plus mFOLFOX should now be considered the standard approach for BRAF V600E-mutant metastatic CRC. But for patients who cannot handle chemotherapy, EC alone may still offer meaningful cancer control with fewer life-disrupting side effects.
Most importantly, this breakthrough shows how personalized medicine is giving new hope to patients with tough-to-treat cancers. The idea that a treatment developed for melanoma could significantly improve outcomes in colorectal cancer is a powerful example of how far cancer care has come—and how much more is possible in the future.
References
Kopetz, S., et al. (2024). BREAKWATER: A Phase III trial of encorafenib + cetuximab with or without chemotherapy for BRAF V600E–mutant metastatic colorectal cancer. Journal of Clinical Oncology.
Overman, M. J., & Kopetz, S. (2019). Precision medicine in colorectal cancer: The molecular landscape and opportunities for intervention. Nature Reviews Clinical Oncology, 16(12), 713–730. https://doi.org/10.1038/s41571-019-0244-z
Van Cutsem, E., et al. (2019). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 30(8), 1386–1422. https://doi.org/10.1093/annonc/mdz176